Schistosomiasis vaccine - Glaxo Wellcome/Medeva

Drug Profile

Schistosomiasis vaccine - Glaxo Wellcome/Medeva

Latest Information Update: 16 Oct 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Evans Vaccines; GlaxoSmithKline; Institut Pasteur
  • Developer Evans Vaccines; GlaxoSmithKline; Nonindustrial source
  • Class Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Schistosomiasis

Most Recent Events

  • 16 Oct 2006 Discontinued - Preclinical for Schistosomiasis in United Kingdom (unspecified route)
  • 15 Jun 2001 No-Development-Reported for Schistosomiasis in United Kingdom (Unknown route)
  • 10 Jan 1995 Preclinical development for Schistosomiasis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top